210 related articles for article (PubMed ID: 31160146)
1. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
[TBL] [Abstract][Full Text] [Related]
2. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K
Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379
[TBL] [Abstract][Full Text] [Related]
4. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
7. Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.
Savulich G; Riccelli R; Passamonti L; Correia M; Deakin JF; Elliott R; Flechais RS; Lingford-Hughes AR; McGonigle J; Murphy A; Nutt DJ; Orban C; Paterson LM; Reed LJ; Smith DG; Suckling J; Tait R; Taylor EM; Sahakian BJ; Robbins TW; Ersche KD
Transl Psychiatry; 2017 Mar; 7(3):e1054. PubMed ID: 28267152
[TBL] [Abstract][Full Text] [Related]
8. Alcohol Cue-Induced Ventral Striatum Activity Predicts Subsequent Alcohol Self-Administration.
Lim AC; Green R; Grodin EN; Venegas A; Meredith LR; Donato S; Burnette E; Ray LA
Alcohol Clin Exp Res; 2020 Jun; 44(6):1224-1233. PubMed ID: 32406553
[TBL] [Abstract][Full Text] [Related]
9. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
10. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
Karl D; Bumb JM; Bach P; Dinter C; Koopmann A; Hermann D; Mann K; Kiefer F; Vollstädt-Klein S
Psychopharmacology (Berl); 2021 Aug; 238(8):2179-2189. PubMed ID: 33846866
[TBL] [Abstract][Full Text] [Related]
11. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
[TBL] [Abstract][Full Text] [Related]
12. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
Am J Drug Alcohol Abuse; 2015 Jan; 41(1):35-44. PubMed ID: 24949564
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
16. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
17. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
18. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
[TBL] [Abstract][Full Text] [Related]
19. Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Beck A; Pelz P; Lorenz RC; Charlet K; Geisel O; Heinz A; Wüstenberg T; Müller CA
Eur Neuropsychopharmacol; 2018 Nov; 28(11):1206-1216. PubMed ID: 30217552
[TBL] [Abstract][Full Text] [Related]
20. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
Bujarski S; MacKillop J; Ray LA
Exp Clin Psychopharmacol; 2012 Jun; 20(3):181-90. PubMed ID: 22429255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
